Fuan Pharmaceutical Announcement, Wholly-owned subsidiary Fuan Pharmaceutical Group Chongqing Bosentan Pharmaceutical Co., Ltd. recently received the approval notice for the application for the listing of chemical raw materials issued by the National Medical Products Administration. The name of the active pharmaceutical ingredient is benzylpenicillin sodium, with registration number Y20.23 billion, manufactured by Bosentan Pharmaceuticals, packaged in 5kg/bottle. Benzylpenicillin sodium is mainly used for various infections caused by penicillin-resistant Staphylococcus aureus, including sepsis, respiratory infections, meningitis, soft tissue infections, etc. It can also be used for mixed infections caused by pyogenic streptococci or pneumococci and penicillin-resistant Staphylococcus aureus. The approval of the above active pharmaceutical ingredient products for listing will enable them to be used in domestic market formulations, further enriching the subsidiary's product line. However, the production and sales time and specific sales situation of the above active pharmaceutical ingredient products are uncertain due to factors such as the progress of GMP compliance inspections, national policies, and changes in the market environment.